Last updated: February 14, 2026
What is the market status of NDC 71930-0022?
NDC 71930-0022 refers to Zepzelca (lurbinectedin), a drug approved by the FDA for use in treating metastatic small cell lung cancer (SCLC). Approved in June 2020, Zepzelca is marketed by Pharma Mar and Jazz Pharmaceuticals. It competes in a niche with limited existing treatments, primarily involving chemotherapy and immunotherapy options.
What is the current market size and patient population?
The small cell lung cancer market addresses approximately 30,000 new cases annually in the U.S.[1], with approximately 70-80% presenting as extensive-stage SCLC at diagnosis. The treatment landscape includes first-line chemotherapy combined with immunotherapy, but options after disease progression are limited, often involving topotecan, irinotecan, or clinical trials.
Approximately 15,000-20,000 patients annually in the U.S. could be eligible for Zepzelca based on line-of-therapy and unresectability.
How is Zepzelca positioned compared to competitors?
Market differentiation:
- FDA approval in the second-line setting for relapsed SCLC.
- Demonstrates favorable response rates compared to traditional chemotherapies.
- Lurbinectedin's mechanism of action involves inhibiting transcription factors, offering a targeted approach.
Key competitors:
- Topotecan (FDA-approved since 1992).
- Irinotecan (used off-label).
- Emerging immunotherapies (e.g., PD-L1 inhibitors in combination with chemotherapy).
Market share estimates:
- Zepzelca's penetration remains modest, with initial sales estimated at $10-15 million in 2021.
- Projected to grow with expanded indications and increased awareness.
What are the price and reimbursement standards?
Pricing details:
- Price per 3 mg vial: approximately $7,200[2].
- Typical treatment course: 2-3 cycles, with total costs in the $15,000 to $25,000 range per patient.
Reimbursement landscape:
- Predominantly covered by Medicare, Medicaid, private insurers.
- Pricing strategies influenced by negotiated discounts, rebates, and the drug's classification as a specialty medication.
What are the projections for future sales?
Short-term outlook (next 2 years):
- Expect sales to increase modestly as awareness improves.
- Additional approvals for third-line or combination use could expand the patient pool.
Long-term potential:
- Incorporation into first-line treatments could significantly expand the addressable market.
- Based on early clinical data, the drug's share could reach $50-100 million annually within five years, assuming successful label expansion.
Factors influencing growth:
- Results from ongoing clinical trials.
- Adoption rates by oncologists.
- Competitive dynamics with emerging therapies.
What are the key regulatory considerations?
Potential expanded indications:
- Trials underway for combination therapies or earlier lines of treatment.
- If approved for additional lines, market size could double or triple.
Pricing negotiations:
- Companies often face pressure to justify high per-dose costs amid limited budgets for oncology drugs.
Patent and exclusivity:
- Patent protection extends until at least 2030, with data exclusivity until 2025.
Summary of key data points
| Data Point |
Details |
| Approved indications |
Second-line SCLC |
| Estimated US patient population |
15,000 - 20,000 annually |
| Current sales (2021) |
$10-15 million |
| Price per 3 mg vial |
$7,200 |
| Projected 5-year revenue (if expanded use) |
$50-100 million |
| Patent expiration |
2030 |
Key Takeaways
- NDC 71930-0022 (Zepzelca) supplies a targeted second-line therapy for SCLC with limited current market share but growth potential.
- The drug's pricing is high, typical for oncology treatments, with significant reimbursement considerations.
- Expanding indications could dramatically increase revenue, driven by clinical trial outcomes and regulatory approvals.
- Market share remains constrained by competing therapies and the slow adoption cycle typical of oncology drugs.
5 FAQs
1. What factors could accelerate Zepzelca’s market growth?
Expanded indications, positive clinical trial results, and increased prescribing from oncologists with early adoption.
2. How does Zepzelca compare in efficacy to traditional chemotherapies?
Clinical trials show response rates of around 35-45% in relapsed SCLC, comparable or slightly better than topotecan.
3. What are the major barriers to market expansion?
High drug costs, limited awareness, and competition from established chemotherapy options.
4. When are potential approvals for new indications expected?
Ongoing trials might lead to early labeling updates within 1-3 years, depending on data outcomes.
5. How will pricing negotiations affect future sales?
Reimbursement pressures and negotiated discounts could limit revenue unless the drug achieves broader use or demonstrates superior efficacy.
References
-
American Cancer Society. "Key Statistics for Small Cell Lung Cancer." (2022). https://cancerstatisticscenter.cancer.org
-
GoodRx. "Zepzelca (lurbinectedin) Price." (2023). https://www.goodrx.com
